Original language | English (US) |
---|---|
Pages (from-to) | viii418 |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology |
Volume | 29 |
DOIs | |
State | Published - Oct 1 2018 |
ASJC Scopus subject areas
- Hematology
- Oncology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). / Babiker, H. M.; Brana, I.; Mahadevan, D.; Owonikoko, T. K.; Calvo, E.; Rischin, D.; Moreno, V.; Papadopoulos, K. P.; Crittenden, M.; Formenti, S.; Giralt, J.; Garrido Lopez, P.; Hervás Morón, A.; Mohan, K. K.; Fury, M. G.; Lowy, I.; Stankevich, E.; Feng, M.; Li, J.; Mathias, M.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii418.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
AU - Babiker, H. M.
AU - Brana, I.
AU - Mahadevan, D.
AU - Owonikoko, T. K.
AU - Calvo, E.
AU - Rischin, D.
AU - Moreno, V.
AU - Papadopoulos, K. P.
AU - Crittenden, M.
AU - Formenti, S.
AU - Giralt, J.
AU - Garrido Lopez, P.
AU - Hervás Morón, A.
AU - Mohan, K. K.
AU - Fury, M. G.
AU - Lowy, I.
AU - Stankevich, E.
AU - Feng, M.
AU - Li, J.
AU - Mathias, M.
PY - 2018/10/1
Y1 - 2018/10/1
UR - http://www.scopus.com/inward/record.url?scp=85081950434&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081950434&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdy288.044
DO - 10.1093/annonc/mdy288.044
M3 - Article
C2 - 32137049
VL - 29
SP - viii418
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
ER -